5-Bromo-DMT Stats & Data

• Identity and occurrence: 5‑Bromo‑DMT is a brominated DMT analogue occurring naturally in several marine sponges (e.g., Verongula rigida, Smenospongia aurea, S. cerebriformis). This supports that samples labeled 5‑Br‑DMT can be legitimate, but also that mislabeling is possible—so verify identity where possible.

• Pharmacology and animal data: In rodent and chick models, 5,6‑dibromo‑DMT showed antidepressant‑like effects, while 5‑bromo‑DMT caused significant hypolocomotion (sedative‑like action). This aligns with user descriptions of a warm, dreamy, lightly visual profile rather than intense 5‑HT2A‑type psychedelia. Extrapolation to humans is uncertain, so cautious titration is warranted.

• Freebase vs salt and ROA: Community reports consistently note that freebase 5‑Br‑DMT vaporizes effectively, whereas the fumarate/salt is poor to smoke and may need conversion to freebase for inhalation; this is typical of tryptamine salts. Avoid open flames and overheating to reduce harshness.

• Avoid insufflation: Multiple reports describe severe burning and mucosal irritation from snorting dry powder; even at 60 mg the pain was extreme and benefits minimal. If someone insists on an intranasal route, buffered aqueous sprays have been used anecdotally to reduce burn, but effects remain mild and data limited.

• Oral use appears weak/inactive without MAOI: Users report minimal effects at 60–120 mg orally. Combining with MAOIs to force oral activity is hazardous due to potentiation and serotonin‑toxicity risks; this route is not recommended.

• Duration and profile: When vaporized, onset is within 1–2 minutes, the peak is short (≈3–20 min), and most are near baseline by 1–2 hours. Effects commonly include soft closed‑eye imagery, mild color/tracer enhancement, and relaxation/sleepiness rather than overwhelming open‑eye hallucinations.

• Combinations and safety: General psychedelic combination guidance applies—avoid with tramadol (seizure risk), be cautious with stimulants/cannabis (unpredictable synergy), and avoid MAOIs unless under clinical supervision. Benzodiazepines can dampen or abort distress but add sedation.

• Drug checking: Indoles/tryptamines react with Ehrlich reagent (purple). While this doesn’t prove identity, a negative Ehrlich raises suspicion for non‑indole adulterants. Use multi‑reagent kits and, where available, lab testing.

• Set/setting and physical safety: Sedation and ataxia at higher doses are reported; use a sitter, remain seated during peaks, and avoid driving/heights. Given sparse human data, allergy test first (≤2 mg inhaled) and titrate.

• Data scarcity: Human pharmacokinetics and long‑term safety are unknown; avoid frequent redosing and extended binges. Treat as a research chemical with conservative dosing and long intervals between trials.